vs
奎斯特诊断（DGX）与汉瑞祥（HSIC）财务数据对比。点击上方公司名可切换其他公司
汉瑞祥的季度营收约是奎斯特诊断的1.2倍（$3.4B vs $2.9B），奎斯特诊断净利率更高（9.7% vs 2.9%，领先6.8%），奎斯特诊断同比增速更快（9.2% vs 7.7%），过去两年奎斯特诊断的营收复合增速更高（9.9% vs 4.1%）
奎斯特诊断是美国头部临床检验服务商，位列《财富》500强，业务覆盖美国、波多黎各、墨西哥及巴西，同时与全球范围内多家医院、诊所保持长期协作关系，为不同地区的客户提供专业临床检验相关服务。
汉瑞祥（Henry Schein, Inc.）是美国的医疗保健产品及服务分销商，业务覆盖全球33个国家和地区，是全球面向诊所类牙科及医疗从业者的最大医疗解决方案供应商。公司连续14年入选Ethisphere评选的「全球最具道德企业」榜单，2025年再次登榜。
DGX vs HSIC — 直观对比
营收规模更大
HSIC
是对方的1.2倍
$2.9B
营收增速更快
DGX
高出1.5%
7.7%
净利率更高
DGX
高出6.8%
2.9%
两年增速更快
DGX
近两年复合增速
4.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.9B | $3.4B |
| 净利润 | $281.0M | $101.0M |
| 毛利率 | — | 30.9% |
| 营业利润率 | 15.4% | 4.7% |
| 净利率 | 9.7% | 2.9% |
| 营收同比 | 9.2% | 7.7% |
| 净利润同比 | 12.0% | 7.4% |
| 每股收益（稀释后） | $2.24 | $0.85 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DGXHSIC
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.8B | $3.4B | ||
| Q3 25 | $2.8B | $3.3B | ||
| Q2 25 | $2.8B | $3.2B | ||
| Q1 25 | $2.7B | $3.2B | ||
| Q4 24 | $2.6B | $3.2B | ||
| Q3 24 | $2.5B | $3.2B | ||
| Q2 24 | $2.4B | $3.1B |
净利润DGXHSIC
| Q1 26 | $281.0M | — | ||
| Q4 25 | $245.0M | $101.0M | ||
| Q3 25 | $245.0M | $101.0M | ||
| Q2 25 | $282.0M | $86.0M | ||
| Q1 25 | $220.0M | $110.0M | ||
| Q4 24 | $222.0M | $94.0M | ||
| Q3 24 | $226.0M | $99.0M | ||
| Q2 24 | $229.0M | $104.0M |
毛利率DGXHSIC
| Q1 26 | — | — | ||
| Q4 25 | 32.4% | 30.9% | ||
| Q3 25 | 33.7% | 30.7% | ||
| Q2 25 | 34.2% | 31.4% | ||
| Q1 25 | 32.5% | 31.6% | ||
| Q4 24 | 32.7% | 31.1% | ||
| Q3 24 | 32.6% | 31.3% | ||
| Q2 24 | 33.5% | 32.5% |
营业利润率DGXHSIC
| Q1 26 | 15.4% | — | ||
| Q4 25 | 13.8% | 4.7% | ||
| Q3 25 | 13.7% | 4.9% | ||
| Q2 25 | 15.9% | 4.7% | ||
| Q1 25 | 13.0% | 5.5% | ||
| Q4 24 | 13.8% | 4.9% | ||
| Q3 24 | 13.3% | 4.9% | ||
| Q2 24 | 14.8% | 5.1% |
净利率DGXHSIC
| Q1 26 | 9.7% | — | ||
| Q4 25 | 8.7% | 2.9% | ||
| Q3 25 | 8.7% | 3.0% | ||
| Q2 25 | 10.2% | 2.7% | ||
| Q1 25 | 8.3% | 3.5% | ||
| Q4 24 | 8.5% | 2.9% | ||
| Q3 24 | 9.1% | 3.1% | ||
| Q2 24 | 9.6% | 3.3% |
每股收益（稀释后）DGXHSIC
| Q1 26 | $2.24 | — | ||
| Q4 25 | $2.18 | $0.85 | ||
| Q3 25 | $2.16 | $0.84 | ||
| Q2 25 | $2.47 | $0.70 | ||
| Q1 25 | $1.94 | $0.88 | ||
| Q4 24 | $1.95 | $0.75 | ||
| Q3 24 | $1.99 | $0.78 | ||
| Q2 24 | $2.03 | $0.80 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $393.0M | $156.0M |
| 总债务越低越好 | $5.7B | $2.3B |
| 股东权益账面价值 | $7.7B | $3.2B |
| 总资产 | $16.7B | $11.2B |
| 负债/权益比越低杠杆越低 | 0.74× | 0.71× |
8季度趋势，按日历期对齐
现金及短期投资DGXHSIC
| Q1 26 | $393.0M | — | ||
| Q4 25 | $420.0M | $156.0M | ||
| Q3 25 | $432.0M | $136.0M | ||
| Q2 25 | $319.0M | $145.0M | ||
| Q1 25 | $188.0M | $127.0M | ||
| Q4 24 | $549.0M | $122.0M | ||
| Q3 24 | $764.0M | $126.0M | ||
| Q2 24 | $271.0M | $138.0M |
总债务DGXHSIC
| Q1 26 | $5.7B | — | ||
| Q4 25 | $5.2B | $2.3B | ||
| Q3 25 | $5.2B | $2.2B | ||
| Q2 25 | $5.2B | $2.1B | ||
| Q1 25 | $5.9B | $2.0B | ||
| Q4 24 | $5.6B | $1.8B | ||
| Q3 24 | $5.6B | $1.9B | ||
| Q2 24 | $3.8B | $1.9B |
股东权益DGXHSIC
| Q1 26 | $7.7B | — | ||
| Q4 25 | $7.2B | $3.2B | ||
| Q3 25 | $7.3B | $3.4B | ||
| Q2 25 | $7.2B | $3.4B | ||
| Q1 25 | $6.9B | $3.3B | ||
| Q4 24 | $6.8B | $3.4B | ||
| Q3 24 | $6.8B | $3.5B | ||
| Q2 24 | $6.6B | $3.5B |
总资产DGXHSIC
| Q1 26 | $16.7B | — | ||
| Q4 25 | $16.2B | $11.2B | ||
| Q3 25 | $16.2B | $11.1B | ||
| Q2 25 | $16.0B | $10.9B | ||
| Q1 25 | $15.8B | $10.5B | ||
| Q4 24 | $16.2B | $10.2B | ||
| Q3 24 | $16.1B | $10.6B | ||
| Q2 24 | $13.9B | $10.3B |
负债/权益比DGXHSIC
| Q1 26 | 0.74× | — | ||
| Q4 25 | 0.72× | 0.71× | ||
| Q3 25 | 0.71× | 0.64× | ||
| Q2 25 | 0.72× | 0.61× | ||
| Q1 25 | 0.85× | 0.59× | ||
| Q4 24 | 0.83× | 0.54× | ||
| Q3 24 | 0.83× | 0.54× | ||
| Q2 24 | 0.58× | 0.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $278.0M | $381.0M |
| 自由现金流经营现金流 - 资本支出 | — | $338.0M |
| 自由现金流率自由现金流/营收 | — | 9.8% |
| 资本支出强度资本支出/营收 | 3.9% | 1.3% |
| 现金转化率经营现金流/净利润 | 0.99× | 3.77× |
| 过去12个月自由现金流最近4个季度 | — | $573.0M |
8季度趋势，按日历期对齐
经营现金流DGXHSIC
| Q1 26 | $278.0M | — | ||
| Q4 25 | $465.0M | $381.0M | ||
| Q3 25 | $563.0M | $174.0M | ||
| Q2 25 | $544.0M | $120.0M | ||
| Q1 25 | $314.0M | $37.0M | ||
| Q4 24 | $464.0M | $204.0M | ||
| Q3 24 | $356.0M | $151.0M | ||
| Q2 24 | $360.0M | $296.0M |
自由现金流DGXHSIC
| Q1 26 | — | — | ||
| Q4 25 | $307.0M | $338.0M | ||
| Q3 25 | $419.0M | $141.0M | ||
| Q2 25 | $436.0M | $88.0M | ||
| Q1 25 | $197.0M | $6.0M | ||
| Q4 24 | $341.0M | $168.0M | ||
| Q3 24 | $250.0M | $117.0M | ||
| Q2 24 | $268.0M | $259.0M |
自由现金流率DGXHSIC
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | 9.8% | ||
| Q3 25 | 14.9% | 4.2% | ||
| Q2 25 | 15.8% | 2.7% | ||
| Q1 25 | 7.4% | 0.2% | ||
| Q4 24 | 13.0% | 5.3% | ||
| Q3 24 | 10.0% | 3.7% | ||
| Q2 24 | 11.2% | 8.3% |
资本支出强度DGXHSIC
| Q1 26 | 3.9% | — | ||
| Q4 25 | 5.6% | 1.3% | ||
| Q3 25 | 5.1% | 1.0% | ||
| Q2 25 | 3.9% | 1.0% | ||
| Q1 25 | 4.4% | 1.0% | ||
| Q4 24 | 4.7% | 1.1% | ||
| Q3 24 | 4.3% | 1.1% | ||
| Q2 24 | 3.8% | 1.2% |
现金转化率DGXHSIC
| Q1 26 | 0.99× | — | ||
| Q4 25 | 1.90× | 3.77× | ||
| Q3 25 | 2.30× | 1.72× | ||
| Q2 25 | 1.93× | 1.40× | ||
| Q1 25 | 1.43× | 0.34× | ||
| Q4 24 | 2.09× | 2.17× | ||
| Q3 24 | 1.58× | 1.53× | ||
| Q2 24 | 1.57× | 2.85× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DGX
暂无分部数据
HSIC
| Global Dental Merchandise | $1.2B | 35% |
| Global Medical | $1.1B | 31% |
| Global Dental Equipment | $536.0M | 16% |
| Global Specialty Products | $422.0M | 12% |
| Global Technology | $173.0M | 5% |
| Global Value Added Services | $64.0M | 2% |
| Equity Method Investee | $14.0M | 0% |
